A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and clostridium difficile diarrhoea in older people admitted to hospital: A multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE)

Health Technology Assessment

Volumn 17, Issue 57, 2013, Pages 1-139

  Allen, S J ^a   Wareham, K ^b   Wang, D ^c   Bradley, C ^d   Sewell, B ^a   Hutchings, H ^a   Harris, W ^e   Dhar, A ^d   Brown, H ^d   Foden, A ^d   Gravenor, M B ^a   Mack, D ^a,f   Phillips, C J ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b MORRISTON HOSPITAL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d DARLINGTON MEMORIAL HOSPITAL   (United Kingdom)

^e SINGLETON HOSPITAL   (United Kingdom)

^f Bioscientia Center for Human Genetics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; CARBAPENEM DERIVATIVE; CEFACLOR; CEFALEXIN; CEFIXIME; CEFOTAXIME; CEFRADINE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUCLOXACILLIN; GENTAMICIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ABDOMINAL PAIN; ABSCESS; ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; AGED; AGITATION; ANEMIA; ANGINA PECTORIS; ANTIBIOTIC ASSOCIATED DIARRHEA; AORTA ANEURYSM; APPENDIX ABSCESS; ARTERY THROMBOSIS; ARTICLE; ASPIRATION PNEUMONIA; BEHAVIOR DISORDER; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BLADDER CANCER; BLEEDING TENDENCY; BRAIN TUMOR; BRONCHIECTASIS; BRONCHOSPASM; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CHOLELITHIASIS; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; CONVULSION; COST EFFECTIVENESS ANALYSIS; CREUTZFELDT JAKOB DISEASE; CYST; DECUBITUS; DEEP VEIN THROMBOSIS; DEHYDRATION; DEMENTIA; DEVICE INFECTION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INTOXICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; DUODENUM ULCER; DYSENTERY; DYSPNEA; EAR DISEASE; EATING DISORDER; ECZEMA; EMPYEMA; ESOPHAGUS CANCER; EXTERNAL OTITIS; FAINTNESS; FEMALE; FOREIGN BODY ASPIRATION; GALLBLADDER DISEASE; GANGRENE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GRAFT INFECTION; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC DISEASE; HEMATOMA; HEMATURIA; HEMORRHOID; HERPES ZOSTER OPHTHALMICUS; HIATUS HERNIA; HIP FRACTURE; HOSPITAL PATIENT; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; IMMUNOPATHOLOGY; INFECTION; INFECTIOUS ARTHRITIS; INFESTATION; INNER EAR DISEASE; INTESTINE ISCHEMIA; INTESTINE POLYP; INTESTINE VOLVULUS; ISCHEMIC HEART DISEASE; JOINT DISLOCATION; KIDNEY DISEASE; KIDNEY FAILURE; LACTOBACILLUS ACIDOPHILUS; LIMB PAIN; LIVER ABSCESS; LIVER CIRRHOSIS; LUNG CANCER; LUNG EDEMA; LUNG EMBOLISM; LUNG FIBROSIS; LUNG INFECTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM ABSCESS; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; METASTASIS; MULTICENTER STUDY; MULTIPLE MYELOMA; MUSCLE SWELLING; MUSCULOSKELETAL DISEASE; MYALGIA; NEOPLASM; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NUTRITIONAL DISORDER; ORAL BLEEDING; PANCREATITIS; PARALLEL DESIGN; PATIENT COMPLIANCE; PEPTIC ULCER; PERITONITIS; PLEURA EFFUSION; PLEURA TUMOR; PNEUMONIA; PNEUMOTHORAX; POLYP; PSOAS ABSCESS; PYELONEPHRITIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RESPIRATORY TRACT DISEASE; RISK FACTOR; SEPSIS; SHUNT INFECTION; SINGLE DRUG DOSE; SKIN DISEASE; SKIN ULCER; SMALL INTESTINE OBSTRUCTION; STOMACH CANCER; SUBDURAL HEMATOMA; SUPRAVENTRICULAR TACHYCARDIA; SWELLING; THORAX DISEASE; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TRIGEMINUS NEURALGIA; ULCER PERFORATION; UMBILICAL HERNIA; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE RETENTION; VASCULAR DISEASE; VERY ELDERLY; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; WOUND DEHISCENCE; WOUND INFECTION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BIFIDOBACTERIUM; CLOSTRIDIUM DIFFICILE; COMORBIDITY; COST-BENEFIT ANALYSIS; DIARRHEA; DOUBLE-BLIND METHOD; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GREAT BRITAIN; HUMANS; INPATIENTS; LACTOBACILLUS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROBIOTICS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS;

EID: 84889608780     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17570     Document Type: Article

References (97)

1. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998;16:292-307. http://dx.doi.org/10.1159/000016879
2. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
3. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008;3:563-78. http://dx.doi.org/10.2217/17460913.3.5.563
4. Viswanathan VK, Mallozzi MJ, Vedantam G. Clostridium difficile infection: an overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes 2010;1:234-42.
5. Antunes LC, Han J, Ferreira RB, Lolic P, Borchers CH, Finlay BB. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother 2011;55:1494-503. http://dx.doi.org/10.1128/AAC.01664-10
6. Badger VO, Ledeboer NA, Graham MB, Edmiston CE Jr. Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. JPEN J Parenter Enteral Nutr 2012;36:645-62. http://dx.doi.org/10.1177/0148607112446703
7. Cartman ST, Heap JT, Kuehne SA, Cockayne A, Minton NP. The emergence of 'hypervirulence' in Clostridium difficile. Int J Med Microbiol 2010;300:387-95. http://dx.doi.org/10.1016/j.ijmm.2010.04.008
8. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006;145:758-64. http://dx.doi.org/10.7326/0003-4819-145-10-200611210-00008
9. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-84. http://dx.doi.org/10.1016/S0140-6736(05)67420-X
10. Wistrom J, Norrby SR, Myhre EB, Eriksson S, Granstrom G, Lagergren L, etal. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001;47:43-50. http://dx.doi.org/10.1093/jac/47.1.43
11. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011;377:63-73. http://dx.doi.org/10.1016/S0140-6736(10)61266-4
12. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-703.
13. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-53. http://dx.doi.org/10.1086/338260
14. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008;46:497-504. http://dx.doi.org/10.1086/526530
15. McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012;18:282-9. http://dx.doi.org/10.1111/j.1469-0691.2011.03571.x
16. Wilcox MH, Cunniffe JG, Trundle C, Redpath C. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 1996;34:23-30. http://dx.doi.org/10.1016/S0195-6701(96)90122-X
17. Vonberg RP, Reichardt C, Behnke M, Schwab F, Zindler S, Gastmeier P. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect 2008;70:15-20. http://dx.doi.org/10.1016/j.jhin.2008.05.004
18. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009;30:57-66.
19. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:1219-27.
20. Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ 2012;184:37-42. http://dx.doi.org/10.1503/cmaj.110543
21. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008;29:823-8.
22. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007;45(Suppl. 2):S112-21. http://dx.doi.org/10.1086/519258
23. Fowler S, Webber A, Cooper BS, Phimister A, Price K, Carter Y, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother 2007;59:990-5. http://dx.doi.org/10.1093/jac/dkm014
24. Joint FAO/WHO Expert Consultation. Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. 2001. URL: http://ftp.fao.org/es/esn/food/probio_report_en.pdf (accessed 10 April 2013).
25. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. Guidelines for the Evaluation of Probiotics in Food. 2002. URL: http://ftp.fao.org/es/esn/food/wgreport2.pdf (accessed 16 July 2013).
26. Hempel S, Newberry S, Ruelaz A, Wang Z, Miles JN, Suttorp MJ, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess 2011;200:1-645.
27. Hammerman C, Bin-Nun A, Kaplan M. Safety of probiotics: comparison of two popular strains. BMJ 2006;333:1006-8. http://dx.doi.org/10.1136/bmj.39010.630799.BE
28. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010;298:G807-19. http://dx.doi.org/10.1152/ajpgi.00243.2009
29. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22. http://dx.doi.org/10.1111/j.1572-0241.2006.00465.x
30. Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002;16:1461-7. http://dx.doi.org/10.1046/j.1365-2036.2002.01318.x
31. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324:1361. http://dx.doi.org/10.1136/bmj.324.7350.1361
32. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006;6:374-82. http://dx.doi.org/10.1016/S1473-3099(06)70495-9
33. Hawrelak JA, Whitten DL, Myers SP. Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion 2005;72:51-6. http://dx.doi.org/10.1159/000087637
34. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004;7:59-62.
35. Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc 2001;76:883-9. http://dx.doi.org/10.4065/76.9.883
36. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-48.
37. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96:981-8.
38. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-4. http://dx.doi.org/10.3109/00365529709011203
39. UK Department of Health. Clostridium difficile infection: how to deal with the problem. London, UK: Department of Health; 2008.
40. Ware JE Jr., Kosinski M, Turner-Bowker DM, Gandek B. User's Manual for the SF-12v2 Health Survey (with a Supplement Documenting SF-12v2 Health Survey). Lincoln, RI: QualityMetric Incorporated; 2002.
41. International Conference on Harmonisation. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines for Good Clinical Practice. 1996. URL: www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html (accessed 10 April 2013).
42. British National Formulary. URL: www.bnf.org/bnf/index.htm (accessed September 2012).
43. MedDRA. MedDRA Term Selection: Points To Consider. ICH-endorsed guide for MedDRA users, 2011. URL: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/MedDRA/MedDRA_Documents/MedDRA_Term_Selection/Release_4.2_based_on_14.1/TermSelection_PTC_R4.2_October2011.pdf (accessed 10 April 2013).
44. Department of Health. NHS reference costs 2011. 2012; URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_131140 (accessed December 2012).
45. Curtis L. Unit Costs Of Health and Social Care 2011. Canterbury: PSSRU, University of Kent; 2011.
46. Joint Formulary Committee. British National Formulary (online). BMJ Group and Pharmaceutical Press, 2012. URL: www.medicinescomplete.com (accessed January 2013).
47. Young TA. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 2005;23:1229-42. http://dx.doi.org/10.2165/00019053-200523120-00007
48. Abubakar I, Irvine L, Aldus CF, Wyatt GM, Fordham R, Schelenz S, et al. A systematic review of the clinical, public health and cost-effectiveness of rapid diagnostic tests for the detection and identification of bacterial intestinal pathogens in faeces and food. Health Technol Assess 2007;11(36):1-216.
49. Burkart NE, Kwaan MR, Shepela C, Madoff RD, Wang Y, Rothenberger DA, et al. Indications and relative utility of lower endoscopy in the management of Clostridium difficile infection. Gastroenterol Res Pract 2011;2011:626582. http://dx.doi.org/10.1155/2011/626582
50. Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012;99:1501-13.
51. Doan L, Forrest H, Fakis A, Craig J, Claxton L, Khare M. Clinical and cost effectiveness of eight disinfection methods for terminal disinfection of hospital isolation rooms contaminated with Clostridium difficile 027. J Hosp Infect 2012;82:114-21. http://dx.doi.org/10.1016/j.jhin.2012.06.014
52. Public Health Wales. All Wales Commentaries: Clostridium difficile Reports. 2012. URL: http://www.wales.nhs.uk/sites3/page.cfm?orgid=379&pid=18490 (accessed 25 June 2013).
53. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. 2008. URL: http://www.nice.org.uk/media/4A6/0F/SelectedFurtherReading210708.pdf (accessed September 2012).
54. Thielman NM, Rust PF, Guerrant RL. Criterion-related validity of a diarrhea questionnaire in HIV-infected patients. Dig Dis Sci 2002;47:1421-6.
55. Rockwood TH, Church JM, Fleshman JW, Kane RL, Mavrantonis C, Thorson AG, et al. Fecal incontinence quality of life scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum 2000;43:9-16. http://dx.doi.org/10.1007/BF02237236
56. Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2012;35:1355-69. http://dx.doi.org/10.1111/j.1365-2036.2012.05104.x
57. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012;7:e34938. http://dx.doi.org/10.1371/journal.pone.0034938
58. Avadhani A, Miley H. Probiotics for prevention of antibiotic-associated diarrhea and Clostridium difficile-associated disease in hospitalized adults - a meta-analysis. J Am Acad Nurse Pract 2011;23:269-74. http://dx.doi.org/10.1111/j.1745-7599.2011.00617.x
59. Kale-Pradhan PB, Jassal HK, Wilhelm SM. Role of Lactobacillus in the prevention of antibiotic-associated diarrhea: a meta-analysis. Pharmacotherapy 2010;30:119-26.
60. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012;307:1959-69.
61. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009;15:274-80. http://dx.doi.org/10.1016/j.anaerobe.2009.09.002
62. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011;11:CD004827. http://dx.doi.org/10.1002/14651858.CD004827
63. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature 2011;473:174-80. http://dx.doi.org/10.1038/nature10187
64. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011;108 (Suppl. 1):4586-91. http://dx.doi.org/10.1073/pnas.1000097107
65. Claesson MJ, Jeffery IB, Conde S, Power SE, O'Connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012;488:178-84. http://dx.doi.org/10.1038/nature11319
66. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005;173: 167-70. http://dx.doi.org/10.1503/cmaj.050350
67. Johnston BC, Ma SS, Goldenberg JZ, Thorlund K, Vandvik PO, Loeb M, et al. Probiotics for the Prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012;18:878-88. http://dx.doi.org/10.7326/0003-4819-157-12-201212180-00563
68. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:651-9. http://dx.doi.org/10.1016/S0140-6736(08)60207-X
69. Sand J, Nordback I. Probiotics in severe acute pancreatitis. Lancet 2008;371:634-5. http://dx.doi.org/10.1016/S0140-6736(08)60284-6
70. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012;107:1001-10.
71. Thachil J. Overprescribing PPIs: time for a hospital antacid policy on Clostridium difficile. BMJ 2008;336:109.
72. Kolling GL, Wu M, Warren CA, Durmaz E, Klaenhammer TR, Guerrant RL. Lactic acid production by Streptococcus thermophilus alters Clostridium difficile infection and in vitro Toxin A production. Gut Microbes 2012;3:523-9. http://dx.doi.org/10.4161/gmic.21757
73. Chapman CM, Gibson GR, Rowland I. Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr 2011;50:1-17. http://dx.doi.org/10.1007/s00394-010-0166-z
74. Timmerman HM, Koning CJ, Mulder L, Rombouts FM, Beynen AC. Monostrain, multistrain and multispecies probiotics - a comparison of functionality and efficacy. Int J Food Microbiol 2004;96:219-33. http://dx.doi.org/10.1016/j.ijfoodmicro.2004.05.012
75. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010;16:2202-22.
76. Health Protection Agency. Results from the mandatory Clostridium difficile reporting scheme. Acute Trust Counts and Rates by Quarter and Financial year-April 2007 onwards. 2012. URL: www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/ClostridiumDifficile/EpidemiologicalData/MandatorySurveillance/cdiffMandatoryReportingScheme/ (accessed 25 June 2013).
77. Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol 2009;47:3211-17. http://dx.doi.org/10.1128/JCM.01082-09
78. Novak-Weekley SM, Marlowe EM, Miller JM, Cumpio J, Nomura JH, Vance PH, et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol 2010;48:889-93. http://dx.doi.org/10.1128/JCM.01801-09
79. Chapin KC, Dickenson RA, Wu F, Andrea SB. Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn 2011;13:395-400. http://dx.doi.org/10.1016/j.jmoldx.2011.03.004
80. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 1991;35:208-10. http://dx.doi.org/10.1128/AAC.35.1.208
81. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011;53:42-8. http://dx.doi.org/10.1093/cid/cir301
82. Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012;28:1-9. http://dx.doi.org/10.1097/MOG.0b013e32834bc9a9
83. Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009;29:97-103. http://dx.doi.org/10.1111/j.1365-2036.2008.03848.x
84. Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr 2010;91:687-703. http://dx.doi.org/10.3945/ajcn.2009.28759
85. Erminia R, Ilaria B, Tiziana M, Silvia P, Antonio N, Pierpaolo D, et al. HRQoL questionnaire evaluation in lactose intolerant patients with adverse reactions to foods. Intern Emerg Med 2013;8:493-6. http://dx.doi.org/10.1007/s11739-011-0630-7
86. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009;9:15. http://dx.doi.org/10.1186/1471-230X-9-15
87. Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol. 2000;95:67-71. http://dx.doi.org/10.1016/S0002-9270(99)00794-7
88. Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res 2009;9:417-22. http://dx.doi.org/10.1586/erp.09.53
89. Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol 2011;4:185-97. http://dx.doi.org/10.1177/1756283X11399115
90. Kamdeu Fansi AA, Guertin JR, LeLorier J. Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. J Med Econ 2012;15:53-60. http://dx.doi.org/10.3111/13696998.2011.629015
91. Cimperman L, Bayless G, Best K, Diligente A, Mordarski B, Oster M, et al. A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol 2011;45:785-9. http://dx.doi.org/10.1097/MCG.0b013e3182166a42
92. MacGowan AP, Feeney R, Brown I, McCulloch SY, Reeves DS, Lovering AM. Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 1997;39:537-41. http://dx.doi.org/10.1093/jac/39.4.537
93. Al-Eidan FA, McElnay JC, Scott MG, Kearney MP. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharm Ther 2000;25:101-9. http://dx.doi.org/10.1046/j.1365-2710.2000.00266.x
94. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636-41. http://dx.doi.org/10.1038/ajg.2010.11
95. Song HJ, Kim JY, Jung SA, Kim SE, Park HS, Jeong Y, et al. Effect of probiotic Lactobacillus (Lacidofil(R) cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study. J Korean Med Sci 2010;25:1784-91.
96. Cremonini F, Videlock EJ. Probiotics are associated with a decreased risk of antibiotic-associated diarrhoea. Evid Based Med 2013;18:71-2. http://dx.doi.org/10.1136/eb-2012-100863
97. Ciorba MA. A gastroenterologist's guide to probiotics. Clin Gastroenterol Hepatol 2012;10: 960-8. http://dx.doi.org/10.1016/j.cgh.2012.03.024